期刊文献+

骨髓增生异常综合征的疗效标准 被引量:11

原文传递
导出
作者 肖志坚
出处 《国际输血及血液学杂志》 CAS 2006年第5期385-386,共2页 International Journal of Blood Transfusion and Hematology
  • 相关文献

参考文献5

  • 1Steensma DP, Tefferi A. The myelodysplastic syndrome (s) : a perspective and review highlighting current controversies, Leuk Res, 2003, 27(9):95-120. 被引量:1
  • 2Cheson BD, Bennett JM, Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood, 2000,96(12):3671-3674. 被引量:1
  • 3Tefferi A, Barosi G, Mesa RA, et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia; On behalf of the IWG for myelofibrosis research and treatment (IWG-MRT). Blood, 2006,May 4, Epub ahead of print. 被引量:1
  • 4Cheson BD, Bennett JM, Kopecky K J, et al. Revised recommendatiom of the International Working Group for Diagnosis, Standardization of response criteria, treatment outcomes, an Reporting startdards for therapeutic trials in acute myeloid leukemia. J Clin Oncol,2003,21(24) :4642-4649. 被引量:1
  • 5Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms.Blood, 2002,100(7) : 2292-2302. 被引量:1

同被引文献52

  • 1邸海侠,王茂生,杨淑莲,侯伟,乌松雨,周振环,李振丽,闫金玉,赵晓民,孙长勇.骨髓增生异常综合征中医证候学分证50例探究[J].河北中医,2006,28(10):737-738. 被引量:5
  • 2肖志坚.骨髓增生异常综合征的诊断和治疗认识现况[J].国际输血及血液学杂志,2007,30(1):1-4. 被引量:9
  • 3刘嵘,濮德敏.雄黄的研究进展[J].时珍国医国药,2007,18(4):982-984. 被引量:38
  • 4肖志坚,郝玉书.骨髓增生异常综合征的治疗选择[J].中华内科杂志,2007,46(4):265-267. 被引量:7
  • 5Omoto E,Deguchi S,Takaba S,et al. Low dose melphalan for treatment of high risk myelody splastic syndromes. Leukemia, 1996,10 (4) :609-614. 被引量:1
  • 6Robak T, Szmigielska-Kaplon A, Urbanska-Rys H, et al. Efficacy and toxicity of low-dose melphalan in myelodysplastic syndromes and acute myeloid leukemia with multilineage dysplasia. Neoplasma, 2003,50(3):172-175. 被引量:1
  • 7Omoto E,Deguehi S,Takaba S,et al.Low-dose melphalan for treatment of high-risk myelodysplastic syndromes.Leukemia,1996,10:609-614. 被引量:1
  • 8Denzlinger C,Bowen D,Benz D,et al.Low-dose melphalan induces favourable responses in elderly patients with high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia.Br J Haematol,2000,108:93-95. 被引量:1
  • 9Omoto E, Deguchi S, Takaba S, et al. Low - dose melphalan for treatment of high - risk myelodysplastic syndromes [ J]. Leukemia, 1996,10:609 - 614. 被引量:1
  • 10Raza A,Lisak L,Billmeier J,et al. Phase II study of topotecan and thalidomide in patients with high -risk myelodysplastic syndromes[ J]. Leuk lymphoma,2006,47 ( 3 ) : 433 - 440. 被引量:1

引证文献11

二级引证文献40

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部